ES2605494T3 - Sales de sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benzo[d]imidazol-2-amina, preparación y uso de las mismas - Google Patents

Sales de sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benzo[d]imidazol-2-amina, preparación y uso de las mismas Download PDF

Info

Publication number
ES2605494T3
ES2605494T3 ES13815780.5T ES13815780T ES2605494T3 ES 2605494 T3 ES2605494 T3 ES 2605494T3 ES 13815780 T ES13815780 T ES 13815780T ES 2605494 T3 ES2605494 T3 ES 2605494T3
Authority
ES
Spain
Prior art keywords
propyl
diisobutylamino
piperazin
imidazol
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13815780.5T
Other languages
English (en)
Spanish (es)
Inventor
Stéphane BURLET
Cécilia ESTRELLA
Mathieu BARRIER
Patricia Melnyk
Nicolas Sergeant
Luc Buee
Philippe Verwaerde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Lille 2 Droit et Santé
Institut National de la Santé et de la Recherche Médicale
Alzprotect SAS
Original Assignee
Université Lille 2 Droit et Santé
Institut National de la Santé et de la Recherche Médicale
Alzprotect SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Lille 2 Droit et Santé, Institut National de la Santé et de la Recherche Médicale, Alzprotect SAS filed Critical Université Lille 2 Droit et Santé
Application granted granted Critical
Publication of ES2605494T3 publication Critical patent/ES2605494T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13815780.5T 2012-12-27 2013-12-27 Sales de sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benzo[d]imidazol-2-amina, preparación y uso de las mismas Active ES2605494T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP12306690 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (1)

Publication Number Publication Date
ES2605494T3 true ES2605494T3 (es) 2017-03-14

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13815780.5T Active ES2605494T3 (es) 2012-12-27 2013-12-27 Sales de sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benzo[d]imidazol-2-amina, preparación y uso de las mismas

Country Status (23)

Country Link
US (3) US9562018B2 (enExample)
EP (1) EP2938597B1 (enExample)
JP (1) JP6384923B2 (enExample)
KR (1) KR102115060B1 (enExample)
CN (1) CN105008333B (enExample)
AU (2) AU2013369288B2 (enExample)
BR (1) BR112015015474B1 (enExample)
CA (1) CA2895285C (enExample)
DK (1) DK2938597T3 (enExample)
ES (1) ES2605494T3 (enExample)
HR (1) HRP20161612T2 (enExample)
HU (1) HUE030930T2 (enExample)
IL (1) IL239450B (enExample)
LT (1) LT2938597T (enExample)
MX (1) MX363367B (enExample)
NZ (1) NZ708959A (enExample)
PL (1) PL2938597T3 (enExample)
PT (1) PT2938597T (enExample)
RS (1) RS55511B1 (enExample)
RU (1) RU2655454C2 (enExample)
SI (1) SI2938597T1 (enExample)
WO (1) WO2014102339A1 (enExample)
ZA (1) ZA201504521B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008333B (zh) 2012-12-27 2018-02-09 雅尔兹普罗泰特公司 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途
HK1245272B (en) 2015-03-16 2019-09-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN116249693A (zh) * 2020-10-01 2023-06-09 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐，其制备及其用途
JP7500875B2 (ja) * 2020-10-07 2024-06-17 アルツプロテクト 運動ニューロン疾患及び神経筋接合部障害の処置のためのｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミン硫酸塩及びそれらの溶媒和物の使用
IL313403A (en) * 2021-12-20 2024-08-01 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS
ES3075524T3 (en) 2022-03-25 2026-08-05 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP2001500162A (ja) * 1997-06-12 2001-01-09 トランジェーヌ、ソシエテ、アノニム 少なくとも１種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用
CN1325397A (zh) * 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
EP1809288B1 (en) * 2004-11-10 2011-09-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
CN105008333B (zh) * 2012-12-27 2018-02-09 雅尔兹普罗泰特公司 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途

Also Published As

Publication number Publication date
HUE030930T2 (hu) 2017-06-28
LT2938597T (lt) 2017-01-25
BR112015015474B1 (pt) 2022-04-19
US20190381036A1 (en) 2019-12-19
AU2013369288A8 (en) 2015-07-16
PT2938597T (pt) 2016-12-09
NZ708959A (en) 2019-11-29
RS55511B1 (sr) 2017-05-31
HRP20161612T1 (hr) 2017-01-27
AU2018202218A1 (en) 2018-04-26
US10772884B2 (en) 2020-09-15
AU2013369288B2 (en) 2018-02-22
CN105008333B (zh) 2018-02-09
AU2013369288A1 (en) 2015-07-02
US10537569B2 (en) 2020-01-21
EP2938597B1 (en) 2016-10-26
KR102115060B1 (ko) 2020-05-25
DK2938597T3 (en) 2017-01-09
BR112015015474A2 (enExample) 2017-08-15
US20170151235A1 (en) 2017-06-01
MX363367B (es) 2019-03-20
HRP20161612T2 (hr) 2017-02-24
HK1215582A1 (en) 2016-09-02
IL239450A0 (en) 2015-07-30
EP2938597A1 (en) 2015-11-04
RU2655454C2 (ru) 2018-05-29
US9562018B2 (en) 2017-02-07
ZA201504521B (en) 2016-11-30
RU2015130671A (ru) 2017-01-30
US20160108003A1 (en) 2016-04-21
CA2895285A1 (en) 2014-07-03
JP2016503813A (ja) 2016-02-08
AU2018202218B2 (en) 2019-02-21
CN105008333A (zh) 2015-10-28
SI2938597T1 (sl) 2017-03-31
WO2014102339A1 (en) 2014-07-03
MX2015008502A (es) 2015-12-16
IL239450B (en) 2018-06-28
KR20150105313A (ko) 2015-09-16
CA2895285C (en) 2021-03-30
JP6384923B2 (ja) 2018-09-05
PL2938597T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
ES2875384T3 (es) Forma cristalina del inhibidor de la quinasa BTK y método de preparación del mismo
ES2704048T3 (es) Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina-2,3-disustituida y su uso como inhibidores de bromodominio
ES2920449T3 (es) Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida
ES2389565T3 (es) Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas
ES2654362T3 (es) Furopiridinas como inhibidores de bromodominio
ES2623608T3 (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida
ES2659549T3 (es) Sales cristalinas de Raltegravir sódico
ES2707726T3 (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
US11242341B2 (en) Solid state forms of valbenazine
ES2705623T3 (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
ES2769255T3 (es) Métodos para fabricar inhibidores de la proteína desacetilasa
ES2892161T3 (es) Preparación de derivados de ácido 2-([1,2,3]triazol-2-il)-benzoico
EP3582773A1 (en) Processes for preparing ag-10, its intermediates, and salts thereof
US20160168143A1 (en) Salts of dasatinib in crystalline form
ES2646095T3 (es) Proceso para la preparación de perampanel
ES2729958T3 (es) Método de producción de compuesto heterocíclico que contiene nitrógeno e intermedio de dicho compuesto heterocíclico que contiene nitrógeno
ES2563153T3 (es) Sal de un inhibidor de enzima fosfodiesterasa 10
ES2784826T3 (es) Forma cristalina de un compuesto de 4H-pirazol[1,5-]benzimidazol, procedimiento de preparación de la misma e intermediario de la misma
CA2993356C (en) Processes for preparing an fgfr inhibitor
US20140128444A1 (en) Novel crystalline salts of asenapine with organic di-acids and tri-acids
ES2237186T3 (es) Modificacion cristalina b del acido 8-ciano-1-ciclopropil-7-(1s,6s-2,8-diazabiciclo (4.3.0)-6fluoro-1,4-dihidro-4-oxo-3-quinolincarboxilico.
ES2928785T3 (es) Sal de edaravona
ES2815924T3 (es) Forma D1 cristalina altamente estable de la sal de monoetanolamina de eltrombopag
ES2905962T3 (es) Procedimiento para la fabricación de la forma alfa de vortioxetina HBr
US10941150B2 (en) Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereof